

Reference number(s)
1904-H

SPECIALTY QUANTITY LIMIT PROGRAM

IBRANCE (palbociclib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Ibrance (palbociclib) 75 mg tablets	21 tablets per 28 days	Breast Cancer: <ul style="list-style-type: none"> • Starting dose: 125 mg once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days • First dose reduction: 100 mg once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days • Second dose reduction: 75mg once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
Ibrance (palbociclib) 100 mg tablets	21 tablets per 28 days	
Ibrance (palbociclib) 125 mg tablets	21 tablets per 28 days	
Ibrance (palbociclib) 75 mg capsules	21 capsules per 28 days	
Ibrance (palbociclib) 100 mg capsules	21 capsules per 28 days	
Ibrance (palbociclib) 125 mg capsules	21 capsules per 28 days	

III. REFERENCE

1. Ibrance capsules [package insert]. New York, NY: Pfizer Inc.; September 2019.
2. Ibrance tablets [package insert]. New York, NY: Pfizer Inc.; November 2019.